A judge has rejected Samsung Bioepis’ bid to discover research and development documents from Pfizer as it seeks to invalidate the drug giant’s patent for its blockbuster autoimmune drug Enbrel, agreeing with Pfizer that it may be “no more than an exercise in fishing”.
Drug giant Pfizer has blasted Samsung Bioepis’ âfishing expeditionâ in its suit alleging infringement of the patent for its blockbuster arthritis drug Enbrel, telling the court the Korean biotech should not be allowed to dig for new grounds of invalidity. Â
Indian generic drug maker Cipla has sued pharmaceutical giants Bristol-Myers Squibb and Pfizer alleging the patents behind their blockbuster deep vein thrombosis drug Eliquis are invalid.
Pharmaceutical giant Pfizer has fired off a lawsuit against four drug companies for allegedly infringing one of its patents for biologic Enbrel by selling a biosimilar of the blockbuster arthritis drug in Australia.
A judge has found Pfizer’s patent for its post-operative injectable painkiller Dynastat is valid and that Australian drug maker Juno Pharmaceuticals infringed the patent by selling generic versions of the drug in Australia.
Five years into a preliminary discovery application for a potential patent infringement lawsuit over a biosimilar of its Enbrel medication, Pfizer has partially succeeded in obtaining further documents from Samsung Bioepis.
Pharmaceutical giants Merck Sharpe & Dohme and Pfizer have resolved a long-running intellectual property dispute over a 2015 patent owned by Pfizer for a pneumococcal vaccine.
The Federal Court has delayed a 15-day hearing in a pneumococcal vaccine patent dispute between Merck Sharp & Dohme and Pfizer after the sudden death of a family member of one of Pfizer’s expert witnesses.
Drug giant Merck Sharp & Dohme has brought a cross appeal in its long-running intellectual property dispute with Pfizer’s Wyeth over the top selling Prevnar 13 pneumococcal vaccine.
Pfizer unit Wyeth is seeking to overturn part of a judge’s decision in its high-stakes patent dispute with Merck Sharp & Dohme that found claims in two of its patents relating to the blockbuster Prevnar 13 pneumococcal vaccine were invalid.